Methofill (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, which is essential for converting folate into its active form needed for DNA, RNA and protein synthesis. This inhibition limits the growth of rapidly dividing cells such as immune cells and cancer cells, while also increasing extracellular adenosine that dampens inflammatory pathways.

The specific dose of Methofill is individualized by the prescribing clinician based on the patient’s diagnosis, disease severity, body surface area, renal and hepatic function, and response to therapy. Dosage adjustments are made during treatment according to laboratory monitoring and clinical assessment.

Methofill is classified as Pregnancy Category X, indicating it is contraindicated in pregnancy because it can cause fetal harm. It is also not recommended while breastfeeding, as methotrexate can be excreted in breast milk and may affect the infant. Effective contraception is required for women of child‑bearing potential.

To request Methofill, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Compared with biologic agents, methotrexate is a small‑molecule drug that can be administered subcutaneously and is generally less costly. Its dual anti‑inflammatory and antiproliferative actions make it useful in both autoimmune diseases and certain cancers, whereas many biologics target only specific cytokines. However, methotrexate requires regular laboratory monitoring for toxicity.

Methofill should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight and extreme temperature fluctuations. Do not refrigerate or freeze unless the specific packaging instructions indicate otherwise.

Methofill is supplied as a sterile solution for subcutaneous injection. A healthcare professional administers the dose using a suitable needle, typically into the abdomen or thigh, following aseptic technique. The injection site should be rotated to minimize local irritation.

Patients should be alert for signs of severe liver toxicity (jaundice, dark urine), pulmonary complications (persistent cough, shortness of breath), and bone‑marrow suppression (unexplained bruising, infections, fatigue). Any of these symptoms require immediate medical evaluation.

Methofill is contraindicated in pregnant women, individuals with known hypersensitivity to methotrexate, patients with severe hepatic impairment, uncontrolled infections, and those receiving live vaccines. Caution is also advised for patients with significant renal dysfunction or pre‑existing bone‑marrow disorders.